Startups Stand Out As 13 Biotechs Raise More Than $409m
This article was originally published in Scrip
Executive Summary
Venture capital and other private equity investment is booming with 13 recent drug developer financings totaling more than $409m, including 10 startups with some large Series A rounds, showing that the biotechnology industry remains attractive to investors even if the window is closing for initial public offerings in the US.
You may also be interested in...
Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.